Targeted Oncology

, Volume 12, Issue 4, pp 475–485 | Cite as

Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study

  • Maya Gottfried
  • Jaafar Bennouna
  • Igor Bondarenko
  • Jean-Yves Douillard
  • David F. Heigener
  • Maciej Krzakowski
  • Anders Mellemgaard
  • Silvia Novello
  • Sergei Orlov
  • Yvonne Summers
  • Joachim von Pawel
  • Julia Stöhr
  • Rolf Kaiser
  • Martin Reck
Original Research Article

Abstract

Background

Nintedanib is a triple angiokinase inhibitor approved with docetaxel for adenocarcinoma non-small cell lung cancer after first-line chemotherapy (FLT). In the phase III LUME-Lung 1 study, overall survival (OS) was significantly longer with nintedanib/docetaxel than with placebo/docetaxel in all adenocarcinoma patients and those with time from start of FLT (TSFLT) <9 months.

Objective

This study sought to extend analyses from the LUME-Lung 1 study, specifically for adenocarcinoma patients, to explore the impact of clinically relevant characteristics on outcomes such as time to progression after FLT.

Patients and Methods

Exploratory analyses were conducted of the overall and European LUME-Lung 1 adenocarcinoma population according to age, prior therapy, and tumor dynamics. Analyses also used TSFLT and time from end of FLT (TEFLT).

Results

Treatment with nintedanib/docetaxel significantly improved OS in European patients independently of age or prior therapy. Analyses of several patient subgroups showed improvements in median OS: TSFLT <6 months, 9.5 versus 7.5 months (hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.55–0.98); chemorefractory to FLT, 9.1 versus 6.9 months (HR 0.72, 95% CI 0.52–0.99); progressive disease (PD) as best response to FLT, 9.8 versus 6.3 months (HR 0.62, 95% CI 0.41–0.94); TEFLT ≤6 months, 11.3 versus 8.2 months (HR 0.75, 95% CI 0.61–0.92); and TEFLT <3 months, 11.0 versus 8.0 months (HR 0.74, 95% CI 0.58–0.94).

Conclusions

Nintedanib/docetaxel demonstrated significant OS benefits in adenocarcinoma patients, which were more pronounced in patients with shorter TSFLT or TEFLT, or with PD as best response to FLT.

This study was registered at ClinicalTrials.gov: NCT00805194.

Notes

Acknowledgments

Analyses were conducted by Boehringer Ingelheim. The authors would like to thank the study investigators, study center staff, and all trial participants and their families.

Compliance with Ethical Standards

Funding

The studies on which this analysis was based, were sponsored by Boehringer Ingelheim. Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Aurora O’Brate, PhD, of inVentiv Medical Communications, UK, during the preparation of this manuscript.

Conflicts of Interest

JB has received consulting fees/honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, and Roche. J-YD has received a research grant from Merck Serono for his institution and consulting fees/honorarium and payment for lectures/speakers bureaus from Amgen, AstraZeneca, Bayer, Roche, Sanofi, and Sirtex. AM has received consulting fees/honorarium (advisory board) from Boehringer Ingelheim. DFH has received consulting fees/honoraria from Boehringer Ingelheim, Eli Lilly, Hoffmann-la Roche, and Bristol-Myers Squibb. YS has received consulting fees/honoraria (advisory board), support for travel to a conference, and payment for lectures/speakers bureaus from Boehringer Ingelheim. SN has received payment for lectures/speakers bureaus from Eli Lilly, Merck Sharp & Dohme, Bristol-Myers Squibb, Roche, and AstraZeneca. JS is an employee of Boehringer Ingelheim Pharma GmbH & Co. KG. RK is an employee of Boehringer Ingelheim Pharma GmbH & Co. KG and an applicant on a pending patent for nintedanib. MR has received consulting fees/honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Hoffmann-La Roche, Merck Sharp & Dohme, Novartis, and Pfizer. MG, IB, JvP, MK, and SO have no conflicts of interest to disclose.

Supplementary material

11523_2017_517_MOESM1_ESM.pdf (289 kb)
ESM 1 (PDF 289 kb).

References

  1. 1.
    Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68(12):4774–82.CrossRefPubMedGoogle Scholar
  2. 2.
    Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15(2):143–55.CrossRefPubMedGoogle Scholar
  3. 3.
    Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39.CrossRefPubMedGoogle Scholar
  4. 4.
    Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372(9652):1809–18.CrossRefPubMedGoogle Scholar
  5. 5.
    Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa survival evaluation in lung cancer). Lancet. 2005;366(9496):1527–37.CrossRefPubMedGoogle Scholar
  6. 6.
    von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17(2):658–67.CrossRefGoogle Scholar
  7. 7.
    Ramlau R, Gervais R, Krzakowski M, von Pawel J, Kaukel E, Abratt RP, et al. Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. J Clin Oncol. 2006;24(18):2800–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Gaschler-Markefski B, Sikken P, Heymach JV, Gottfried M, Mellemgaard A, Novello S, et al. Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer. ESMO Open. 2017;2(1):e000102.CrossRefGoogle Scholar
  10. 10.
    Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–51.CrossRefPubMedGoogle Scholar
  11. 11.
    Moro-Sibilot D, Smit E, de Castro CJ, Lesniewski-Kmak K, Aerts J, Villatoro R, et al. Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study. Lung Cancer. 2015;88(2):215–22.CrossRefPubMedGoogle Scholar
  12. 12.
    Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012;13(3):300–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Reck M, Paz-Ares LG, Bidoli P, Cappuzzo F, Dakhil SR, Moro-Sibilot D, et al. Exploratory subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase III study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC). J Clin Oncol. 2016;34(suppl):abstract 9079.Google Scholar
  14. 14.
    European Medicines Agency. Assessment report OPDIVO. 2016.http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/003985/WC500205973.pdf. Accessed 1 Jun 2017.
  15. 15.
    Director’s Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nature Med. 2008;14(8):822–7.CrossRefGoogle Scholar
  16. 16.
    Hilberg F, Haslinger C, Garin-Chesa P, Adolf GR. Molecular correlates of clinical benefit from antiangiogenic therapy for patients with lung adenocarcinoma: a hypothesis. J Clin Oncol. 2014;32:e22080. (abstr)Google Scholar
  17. 17.
    Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50.CrossRefPubMedGoogle Scholar
  18. 18.
    Dawe DE, Ellis PM. The treatment of metastatic non-small cell lung cancer in the elderly: an evidence-based approach. Front Oncol. 2014;4:178.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Earle CC, Tsai JS, Gelber RD, Weinstein MC, Neumann PJ, Weeks JC. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol. 2001;19(4):1064–70.CrossRefPubMedGoogle Scholar
  20. 20.
    Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J Clin Oncol. 2000;18(12):2354–62.CrossRefPubMedGoogle Scholar
  21. 21.
    Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589–97.CrossRefPubMedGoogle Scholar
  22. 22.
    Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist. 2009;14(3):253–63.CrossRefPubMedGoogle Scholar
  23. 23.
    Paz-Ares L, Perol M, Ciuleanu T-E, Kowalyszyn RD, Reck M, Lewanski CR, et al. Exploratory analysis of safety by histology and efficacy in a nonsquamous NSCLC subgroup in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) vs DOC for second-line treatment of stage IV non-small-cell lung cancer (NSCLC). J Clin Oncol. 2015;33(suppl):abstract 8055.Google Scholar
  24. 24.
    Reck M, Mellemgaard A, von Pawel J, Gottfried M, Bondarenko I, Cheng Y, et al. Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel. Lung Cancer. 2015;90(2):267–73.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Maya Gottfried
    • 1
  • Jaafar Bennouna
    • 2
  • Igor Bondarenko
    • 3
  • Jean-Yves Douillard
    • 2
  • David F. Heigener
    • 4
  • Maciej Krzakowski
    • 5
  • Anders Mellemgaard
    • 6
  • Silvia Novello
    • 7
  • Sergei Orlov
    • 8
  • Yvonne Summers
    • 9
  • Joachim von Pawel
    • 10
  • Julia Stöhr
    • 11
  • Rolf Kaiser
    • 12
    • 13
  • Martin Reck
    • 4
  1. 1.Lung Cancer UnitMeir Medical CenterKfar SabaIsrael
  2. 2.Département D’Oncologie MédicaleICO René GauducheauSaint Herblain CedexFrance
  3. 3.Dnepropetovsk Medical Academy, Municipal Clinical Hospital #4DnipropetrovskUkraine
  4. 4.Department of Thoracic Oncology, LungenClinic Grosshansdorf, Airway Research Center North (ARCN)Member of the German Center for Lung Research (DZL)GrosshansdorfGermany
  5. 5.Oncology InstituteWarsawPoland
  6. 6.Department of OncologyHerlev HospitalHerlevDenmark
  7. 7.Thoracic Oncology Unit, AUO San Luigi, Department of OncologyUniversity of TurinTorinoItaly
  8. 8.Department of Thoracic OncologyGOU VPO St Petersburg State Medical UniversitySt PetersburgRussia
  9. 9.Department of Medical OncologyChristie Hospital NHS Foundation TrustManchesterUK
  10. 10.Asklepios Fachkliniken München-GautingGautingGermany
  11. 11.Boehringer Ingelheim Pharma GmbH & Co. KGBiberachGermany
  12. 12.Boehringer Ingelheim Pharma GmbH & Co. KGIngelheim am RheinGermany
  13. 13.Johannes Gutenberg University of MainzMainzGermany

Personalised recommendations